<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BRINTELLIX- vortioxetine hydrobromideÂ tablet, film coatedÂ </strong><br>Takeda Pharmaceuticals America, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BRINTELLIX safely and effectively. See full prescribing information for BRINTELLIX.<br>BRINTELLIX (vortioxetine) tablets, for oral use<br>Initial U.S. Approval: 2013</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning">
<span class="Italics">See full prescribing information for complete boxed warning</span>.</h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants (<a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">5.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">5.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">BRINTELLIX has not been evaluated for use in pediatric patients (<a href="#ID_916a2c92-71f0-4d3d-afef-92cecac25d9e">8.4</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions (<a href="#ID_4f336d1f-a6d7-4042-bde3-a65345475cc0">5.5</a>)   	7/2014 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning">
<span class="Italics">See full prescribing information for complete boxed warning</span>.</h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants (<a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">5.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">5.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">BRINTELLIX has not been evaluated for use in pediatric patients (<a href="#ID_916a2c92-71f0-4d3d-afef-92cecac25d9e">8.4</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BRINTELLIX is indicated for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) (<a href="#i4i_indications_id_4a781764-998b-4b6e-901a-c2975858383e">1</a>, <a href="#i4i_clinical_studies_id_2b92635f-77ec-4a74-903a-362460333e59">14</a>). </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>The recommended starting dose is 10 mg administered orally once daily without regard to meals (<a href="#ID_8f50e394-d306-479d-a660-f633b79b2ae3">2.1</a>).</dd>
<dt>â€¢</dt>
<dd>The dose should then be increased to 20 mg/day, as tolerated (<a href="#ID_8f50e394-d306-479d-a660-f633b79b2ae3">2.1</a>).</dd>
<dt>â€¢</dt>
<dd>Consider 5 mg/day for patients who do not tolerate higher doses (<a href="#ID_8f50e394-d306-479d-a660-f633b79b2ae3">2.1</a>).</dd>
<dt>â€¢</dt>
<dd>BRINTELLIX can be discontinued abruptly. However, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible (<a href="#ID_c732cb90-a954-4fdf-bb9c-2c6cba48c819">2.3</a>).</dd>
<dt>â€¢</dt>
<dd>The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers (<a href="#ID_a2804bb7-7f80-4ab1-9e40-0c8537bc0504">2.6</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">BRINTELLIX is available as 5 mg, 10 mg, 15 mg, and 20 mg immediate release tablets (<a href="#i4i_dosage_form_strength_id_abd13c50-2248-4b61-91b4-00e9d50e7b89">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to vortioxetine or any components of the BRINTELLIX formulation (<a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">4</a>).</dd>
<dt>â€¢</dt>
<dd>Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with BRINTELLIX or within 21 days of stopping treatment with BRINTELLIX. Do not use BRINTELLIX within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start BRINTELLIX in a patient who is being treated with linezolid or intravenous methylene blue (<a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">4</a>).</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> has been reported with serotonergic antidepressants (SSRIs, SNRIs, and others), including with BRINTELLIX, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. Johnâ€™s Wort). If such symptoms occur, discontinue BRINTELLIX and initiate supportive treatment. If concomitant use of BRINTELLIX with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases (<a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">5.2</a>).</dd>
<dt>â€¢</dt>
<dd>Treatment with serotonergic antidepressants (SSRIs, SNRIs, and others) may increase the risk of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients should be cautioned about the increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when BRINTELLIX is coadministered with nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation (<a href="#ID_25158157-1a1c-41af-9cbe-90803d821e5c">5.3</a>).</dd>
<dt>â€¢</dt>
<dd>Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> can occur with antidepressant treatment. Screen patients for bipolar disorder (<a href="#ID_fd0c522f-7828-4663-a0b5-f31387756659">5.4</a>).</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span>: <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle closure glaucoma</span> has occurred in patients with untreated anatomically narrow angles treated with antidepressants (<a href="#ID_4f336d1f-a6d7-4042-bde3-a65345475cc0">5.5</a>).</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> can occur in association with the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>) (<a href="#ID_cf1fdee0-361b-4c20-9f28-327182826a8e">5.6</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence â‰¥5% and at least twice the rate of placebo) were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#i4i_adverse_effects_id_8ac33d8e-c6a8-493a-9d94-7ceffa98817a">6</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Strong inhibitors of CYP2D6: Reduce BRINTELLIX dose by half when a strong CYP2D6 inhibitor (e.g., bupropion, fluoxetine, paroxetine, or quinidine) is coadministered (<a href="#ID_a2804bb7-7f80-4ab1-9e40-0c8537bc0504">2.6</a> and <a href="#ID_29ade52b-7b35-43f2-92fb-be9205691a58">7.3</a>).</dd>
<dt>â€¢</dt>
<dd>Strong CYP Inducers: Consider increasing BRINTELLIX dose when a strong CYP inducer (e.g., rifampin, carbamazepine, or phenytoin) is coadministered for more than 14 days. The maximum recommended dose should not exceed 3 times the original dose (<a href="#ID_5f8755d5-ce1d-402b-9aca-9e575fe495c6">2.7</a> and <a href="#ID_29ade52b-7b35-43f2-92fb-be9205691a58">7.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: Based on animal data, BRINTELLIX may cause fetal harm (<a href="#ID_7b00a858-52a4-43cd-825a-7bb8d77a08d9">8.1</a>).</dd>
<dt>â€¢</dt>
<dd>Nursing Mothers: Discontinue BRINTELLIX or nursing (<a href="#ID_491124cd-7dcc-436a-862a-c0961c784948">8.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Instruction for Use</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Maintenance/Continuation/Extended Treatment</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Discontinuing Treatment</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Use of BRINTELLIX with Other MAOIs such as Linezolid or Methylene Blue</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Use of BRINTELLIX in Known CYP2D6 Poor Metabolizers or in Patients Taking Strong CYP2D6 Inhibitors</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Use of BRINTELLIX in Patients Taking Strong CYP Inducers</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CNS Active Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Potential for Other Drugs to Affect BRINTELLIX</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Potential for BRINTELLIX to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Other Patient Populations</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="_RefID_842f20ae-e2f0-4419-a495-485ef2e9d"></a><a name="section-1"></a><p></p>
<h1>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<p class="First"><span class="Bold">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a trend toward reduced risk with antidepressant use in patients aged 65 and older <span class="Italics">[see <a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">Warnings and Precautions (5.1)</a>].</span></span></p>
<p><span class="Bold">In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber <span class="Italics">[see <a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">Warnings and Precautions (5.1)</a>].</span></span></p>
<p><span class="Bold">BRINTELLIX has not been evaluated for use in pediatric patients <span class="Italics">[see <a href="#ID_916a2c92-71f0-4d3d-afef-92cecac25d9e">Use in Specific Populations (8.4)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4a781764-998b-4b6e-901a-c2975858383e"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0cd5ffb2-8a6b-485e-b90a-a980c7846534"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First">BRINTELLIX is indicated for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD). The efficacy of BRINTELLIX was established in six 6 to 8 week studies (including one study in the elderly) and one maintenance study in adults <span class="Italics">[see <a href="#i4i_clinical_studies_id_2b92635f-77ec-4a74-903a-362460333e59">Clinical Studies (14)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e19d28bd-36a0-4d25-9ef8-fc0a0ee353c6"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8f50e394-d306-479d-a660-f633b79b2ae3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Instruction for Use</h2>
<p class="First">The recommended starting dose is 10Â mg administered orally once daily without regard to meals. Dosage should then be increased to 20 mg/day, as tolerated, because higher doses demonstrated better treatment effects in trials conducted in the United States. The efficacy and safety of doses above 20 mg/day have not been evaluated in controlled clinical trials. A dose decrease down to 5 mg/day may be considered for patients who do not tolerate higher doses <span class="Italics">[see <a href="#i4i_clinical_studies_id_2b92635f-77ec-4a74-903a-362460333e59">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf6f1ceb-96a8-43c8-8786-43f11a0c5971"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Maintenance/Continuation/Extended Treatment</h2>
<p class="First">It is generally agreed that acute episodes of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> should be followed by several months or longer of sustained pharmacologic therapy. A maintenance study of BRINTELLIX demonstrated that BRINTELLIX decreased the risk of recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c732cb90-a954-4fdf-bb9c-2c6cba48c819"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Discontinuing Treatment</h2>
<p class="First">Although BRINTELLIX can be abruptly discontinued, in placebo-controlled trials patients experienced transient adverse reactions such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and muscle <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> following abrupt discontinuation of BRINTELLIX 15 mg/day or 20 mg/day. To avoid these adverse reactions, it is recommended that the dose be decreased to 10 mg/day for one week before full discontinuation of BRINTELLIX 15 mg/day or 20 mg/day <span class="Italics">[see <a href="#i4i_adverse_effects_id_8ac33d8e-c6a8-493a-9d94-7ceffa98817a">Adverse Reactions (6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d1775f86-090c-4b76-b46b-b330353f02ce"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</h2>
<p class="First">At least 14 days should elapse between discontinuation of a MAOI intended to treat psychiatric disorders and initiation of therapy with BRINTELLIX to avoid the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>]</span>. Conversely, at least 21 days should be allowed after stopping BRINTELLIX before starting an MAOI intended to treat psychiatric disorders <span class="Italics">[see <a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">Contraindications (4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_830b722e-0789-4361-b3b7-cfcab22ff69b"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Use of BRINTELLIX with Other MAOIs such as Linezolid or Methylene Blue</h2>
<p class="First">Do not start BRINTELLIX in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered <span class="Italics">[see <a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">Contraindications (4)</a>]</span>.</p>
<p>In some cases, a patient already receiving BRINTELLIX therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> in a particular patient, BRINTELLIX should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> for 21 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with BRINTELLIX may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue <span class="Italics">[<a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">see Warnings and Precautions (5.2)</a>]</span>.</p>
<p>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with BRINTELLIX is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with such use <span class="Italics">[see <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2804bb7-7f80-4ab1-9e40-0c8537bc0504"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Use of BRINTELLIX in Known CYP2D6 Poor Metabolizers or in Patients Taking Strong CYP2D6 Inhibitors</h2>
<p class="First">The maximum recommended dose of BRINTELLIX is 10 mg/day in known CYP2D6 poor metabolizers. Reduce the dose of BRINTELLIX by one-half when patients are receiving a CYP2D6 strong inhibitor (e.g., bupropion, fluoxetine, paroxetine, or quinidine) concomitantly. The dose should be increased to the original level when the CYP2D6 inhibitor is discontinued <span class="Italics">[see <a href="#ID_29ade52b-7b35-43f2-92fb-be9205691a58">Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5f8755d5-ce1d-402b-9aca-9e575fe495c6"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Use of BRINTELLIX in Patients Taking Strong CYP Inducers</h2>
<p class="First">Consider increasing the dose of BRINTELLIX when a strong CYP inducer (e.g., rifampin, carbamazepine, or phenytoin) is coadministered for greater than 14 days. The maximum recommended dose should not exceed three times the original dose. The dose of BRINTELLIX should be reduced to the original level within 14 days, when the inducer is discontinued <span class="Italics">[see <a href="#ID_5f8755d5-ce1d-402b-9aca-9e575fe495c6">Drug Interactions (7.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_abd13c50-2248-4b61-91b4-00e9d50e7b89"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">BRINTELLIX is available as immediate-release, film-coated tablets in the following strengths:</p>
<dl>
<dt>â€¢</dt>
<dd>5 mg: 	pink, almond shaped biconvex film coated tablet, debossed with â€œ5â€? on one side and â€œTLâ€? on the  other side</dd>
<dt>â€¢</dt>
<dd>10 mg: 	yellow, almond shaped biconvex film coated tablet, debossed with â€œ10â€? on one side and â€œTLâ€? on the other side</dd>
<dt>â€¢</dt>
<dd>15 mg: 	orange, almond shaped biconvex film coated tablet, debossed with â€œ15â€? on one side and â€œTLâ€? on the other side</dd>
<dt>â€¢</dt>
<dd>20 mg: 	red, almond shaped biconvex film coated tablet, debossed with â€œ20â€? on one side and â€œTLâ€? on the other side</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to vortioxetine or any components of the formulation. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> has been reported in patients treated with BRINTELLIX.</dd>
<dt>â€¢</dt>
<dd>The use of MAOIs intended to treat psychiatric disorders with BRINTELLIX or within 21 days of stopping treatment with BRINTELLIX is contraindicated because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. The use of BRINTELLIX within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated <span class="Italics">[see <a href="#ID_d1775f86-090c-4b76-b46b-b330353f02ce">Dosage and Administration (2.4)</a> and <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>].</span>
</dd>
<dt>Â </dt>
<dd>Starting BRINTELLIX in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see <a href="#ID_830b722e-0789-4361-b3b7-cfcab22ff69b">Dosage and Administration (2.5)</a> and <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_0e6d4856-3681-40d7-9383-d370de9e7af7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_acb6b79c-6549-4e5d-88da-a3542e95d85d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a trend toward reduction with antidepressants compared to placebo in adults aged 65 and older.</p>
<p>The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive-compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of nine antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of two months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <span class="Italics">Table 1</span>.</p>
<table width="100%">
<col width="37%">
<col width="57%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First"><span class="Bold">Table 1. Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Age Range</span></p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Increases Compared to Placebo</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;18</p></td>
<td class="Botrule Lrule Rrule"><p class="First">14 additional cases</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18-24</p></td>
<td class="Botrule Lrule Rrule"><p class="First">5 additional cases</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Decreases Compared to Placebo</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25-64</p></td>
<td class="Botrule Lrule Rrule"><p class="First">1 fewer case</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥65</p></td>
<td class="Botrule Lrule Rrule"><p class="First">6 fewer cases</p></td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric studies. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> have been reported in adult and pediatric patients being treated with antidepressants for MDD as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.</p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for MDD or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers.</span></p>
<p><span class="Bold">Screening Patients for Bipolar Disorder</span></p>
<p>A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that BRINTELLIX is not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with serotonergic antidepressants including BRINTELLIX, when used alone but more often when used concomitantly with other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. Johnâ€™s Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
<p>The concomitant use of BRINTELLIX with MAOIs intended to treat psychiatric disorders is contraindicated. BRINTELLIX should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking BRINTELLIX. BRINTELLIX should be discontinued before initiating treatment with the MAOI <span class="Italics">[see <a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">Contraindications (4)</a></span> Â <span class="Italics">and <a href="#ID_d1775f86-090c-4b76-b46b-b330353f02ce">Dosage and Administration (2.4)</a>]</span>.</p>
<p>If concomitant use of BRINTELLIX with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. Johnâ€™s Wort is clinically warranted, patients should be made aware of a potential increased risk for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases.</p>
<p>Treatment with BRINTELLIX and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_25158157-1a1c-41af-9cbe-90803d821e5c"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">The use of drugs that interfere with serotonin reuptake inhibition, including BRINTELLIX, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to drugs that inhibit serotonin reuptake have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>. </p>
<p>Patients should be cautioned about the increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when BRINTELLIX is coadministered with NSAIDs, aspirin, or other drugs that affect coagulation or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#ID_ba8fe8b4-40d1-4db3-84bc-a201614f1a43">Drug Interactions (7.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fd0c522f-7828-4663-a0b5-f31387756659"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> were reported in &lt;0.1% of patients treated with BRINTELLIX in pre-marketing clinical studies. Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has been reported in a small proportion of patients with major <span class="product-label-link" type="condition" conceptid="444100" conceptname="Mood disorder">affective disorder</span> who were treated with other antidepressants. As with all antidepressants, use BRINTELLIX cautiously in patients with a history or family history of bipolar disorder, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4f336d1f-a6d7-4042-bde3-a65345475cc0"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span>:  The pupillary dilation that occurs following use of many antidepressant drugs, including BRINTELLIX, may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf1fdee0-361b-4c20-9f28-327182826a8e"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> has occurred as a result of treatment with serotonergic drugs. In many cases, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). One case with serum sodium lower than 110 mmol/L was reported in a subject treated with BRINTELLIX in a pre-marketing clinical study. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with a serotonergic antidepressant. Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. Discontinuation of BRINTELLIX in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which can lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. More severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_8ac33d8e-c6a8-493a-9d94-7ceffa98817a"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <span class="Italics">[see <a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">Contraindications (4)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk <span class="Italics">[see <a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see <a href="#ID_25158157-1a1c-41af-9cbe-90803d821e5c">Warnings and Precautions (5.3)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> <span class="Italics">[see <a href="#ID_fd0c522f-7828-4663-a0b5-f31387756659">Warnings and Precautions (5.4)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> <span class="Italics">[see <a href="#ID_cf1fdee0-361b-4c20-9f28-327182826a8e">Warnings and Precautions (5.6)</a>]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_17f143c9-5f58-4444-89f7-676c9459a017"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</p>
<p><span class="Bold">Patient Exposure</span></p>
<p>BRINTELLIX was evaluated for safety in 4746 patients (18 years to 88 years of age) diagnosed with MDD who participated in pre-marketing clinical studies; 2616 of those patients were exposed to BRINTELLIX in 6 to 8 week, placebo-controlled studies at doses ranging from 5 mg to 20 mg once daily and 204 patients were exposed to BRINTELLIX in a 24 week to 64 week placebo-controlled maintenance study at doses of 5 mg to 10 mg once daily. Patients from the 6 to 8 week studies continued into 12â€‘month open-label studies. A total of 2586 patients were exposed to at least one dose of BRINTELLIX in open-label studies, 1727 were exposed to BRINTELLIX for six months and 885 were exposed for at least one year.</p>
<p><span class="Bold">Adverse Reactions Reported as Reasons for Discontinuation of Treatment</span></p>
<p>In pooled 6 to 8 week placebo-controlled studies the incidence of patients who received BRINTELLIX 5 mg/day, 10 mg/day, 15 mg/day and 20 mg/day and discontinued treatment because of an adverse reaction was 5%, 6%, 8% and 8%, respectively, compared to 4% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> was the most common adverse reaction reported as a reason for discontinuation.</p>
<p><span class="Bold">Common Adverse Reactions in Placebo-Controlled MDD Studies</span></p>
<p>The most commonly observed adverse reactions in MDD patients treated with BRINTELLIX in 6 to 8 week placebo-controlled studies (incidence â‰¥5% and at least twice the rate of placebo) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Italics">Table 2</span> shows the incidence of common adverse reactions that occurred in â‰¥2% of MDD patients treated with any BRINTELLIX dose and at least 2% more frequently than in placebo-treated patients in the 6 to 8 week placebo-controlled studies.</p>
<table width="100%">
<col width="24%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="10%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">pruritus generalized</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold">Table 2. Common Adverse Reactions Occurring in â‰¥2% of Patients Treated with any BRINTELLIX Dose and at Least 2% Greater than the Incidence in Placebo-treated Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First"><span class="Bold">System Organ Class Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">BRINTELLIX</span><br><span class="Bold">5 mg/day</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">BRINTELLIX</span><br><span class="Bold">10 mg/day</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">BRINTELLIX</span><br><span class="Bold">15 mg/day</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">BRINTELLIX</span><br><span class="Bold">20 mg/day</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=1013<br>%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=699<br>%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=449<br>%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=455<br>%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=1621<br>%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></p></td>
<td class="Botrule Lrule Rrule" colspan="5"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></p></td>
<td class="Botrule Lrule Rrule" colspan="5"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Psychiatric disorders</p></td>
<td class="Botrule Lrule Rrule" colspan="5"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Skin and subcutaneous tissue disorders</p></td>
<td class="Botrule Lrule Rrule" colspan="5"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> was the most common adverse reaction and its frequency was dose-related <span class="Italics">(Table 2)</span>. It was usually considered mild or moderate in intensity and the median duration was 2 weeks. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> was more common in females than males. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> most commonly occurred in the first week of BRINTELLIX treatment with 15 to 20% of patients experiencing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> after 1 to 2 days of treatment. Approximately 10% of patients taking BRINTELLIX 10 mg/day to 20 mg/day had <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> at the end of the 6 to 8 week placebo-controlled studies.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span></span></p>
<p>Difficulties in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of psychiatric disorders, but they may also be consequences of pharmacologic treatment.</p>
<p>In the MDD 6 to 8 week controlled trials of BRINTELLIX, voluntarily reported adverse reactions related to <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> were captured as individual event terms. These event terms have been aggregated and the overall incidence was as follows. In male patients the overall incidence was 3%, 4%, 4%, 5% in BRINTELLIX 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, respectively, compared to 2% in placebo. In female patients, the overall incidence was &lt;1%, 1%, &lt;1%, 2% in BRINTELLIX 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, respectively, compared to &lt;1% in placebo.</p>
<p>Because voluntarily reported adverse sexual reactions are known to be underreported, in part because patients and physicians may be reluctant to discuss them, the Arizona Sexual Experiences Scale (ASEX), a validated measure designed to identify sexual side effects, was used prospectively in seven placebo-controlled trials. The ASEX scale includes five questions that pertain to the following aspects of sexual function: 1) sex drive, 2) ease of arousal, 3) ability to achieve erection (men) or lubrication (women), 4) ease of reaching orgasm, and 5) orgasm satisfaction.</p>
<p>The presence or absence of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> among patients entering clinical studies was based on their ASEX scores. For patients without <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> at baseline (approximately 1/3 of the population across all treatment groups in each study), <span class="Italics">Table 3</span> shows the incidence of patients that developed treatment-emergent <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> when treated with BRINTELLIX or placebo in any fixed dose group. Physicians should routinely inquire about possible sexual side effects.</p>
<table width="100%">
<col width="10%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="14%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Incidence based on number of subjects with <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> during the study / number of subjects without <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> at baseline. <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual dysfunction</span> was defined as a subject scoring any of the following on the ASEX scale at two consecutive visits during the study: 1) total score â‰¥19; 2) any single item â‰¥5; 3) three or more items each with a score â‰¥4</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>Sample size for each dose group is the number of patients (females:males) without <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> at baseline</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold">Table 3. ASEX Incidence of Treatment Emergent <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">BRINTELLIX</span></p>
<p><span class="Bold">5 mg/day</span></p>
<p>N=65:67<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">BRINTELLIX</span></p>
<p><span class="Bold">10 mg/day</span></p>
<p>N=94:86<a href="#footnote-3" class="Sup">â€ </a></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">BRINTELLIX</span></p>
<p><span class="Bold">15 mg/day</span></p>
<p>N=57:67<a href="#footnote-3" class="Sup">â€ </a></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">BRINTELLIX</span></p>
<p><span class="Bold">20 mg/day</span></p>
<p>N=67:59<a href="#footnote-3" class="Sup">â€ </a></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p>N=135:162<a href="#footnote-3" class="Sup">â€ </a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Females</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">34%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Males</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14%</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Adverse Reactions Following Abrupt Discontinuation of BRINTELLIX Treatment</span></p>
<p>Discontinuation symptoms have been prospectively evaluated in patients taking BRINTELLIX 10 mg/day, 15 mg/day, and 20 mg/day using the Discontinuation-Emergent Signs and Symptoms (DESS) scale in clinical trials. Some patients experienced discontinuation symptoms such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, muscle <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, sudden outbursts of <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> in the first week of abrupt discontinuation of BRINTELLIX 15 mg/day and 20 mg/day.</p>
<p><span class="Bold">Laboratory Tests</span></p>
<p>BRINTELLIX has not been associated with any clinically important changes in laboratory test parameters in serum chemistry (except sodium), hematology and urinalysis as measured in the 6 to 8 week placebo-controlled studies. <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> has been reported with the treatment of BRINTELLIX <span class="Italics">[see <a href="#ID_cf1fdee0-361b-4c20-9f28-327182826a8e">Warnings and Precautions (5.6)</a>]</span>. In the 6-month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to BRINTELLIX during the initial 12-week, open-label phase, there were no clinically important changes in lab test parameters between BRINTELLIX and placebo-treated patients.</p>
<p><span class="Bold">Weight</span></p>
<p>BRINTELLIX had no significant effect on body weight as measured by the mean change from baseline in the 6 to 8 week placebo-controlled studies. In the 6-month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to BRINTELLIX during the initial 12-week, open-label phase, there was no significant effect on body weight between BRINTELLIX and placebo-treated patients.</p>
<p><span class="Bold">Vital Signs</span></p>
<p>BRINTELLIX has not been associated with any clinically significant effects on vital signs, including systolic and diastolic blood pressure and heart rate, as measured in placebo-controlled studies.</p>
<p><span class="Bold">Other Adverse Reactions Observed in Clinical Studies</span></p>
<p>The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.</p>
<p><span class="Italics">Ear and labyrinth disorders â€” </span><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span> â€” </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span> â€” </span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span> â€” </span><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_20b8f4f3-3d01-4ac6-bfff-0abd43788c97"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0838e3d5-2a24-419d-bff0-13cbd5db39fb"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CNS Active Agents</h2>
<p class="First"><span class="Bold">Monoamine Oxidase Inhibitors</span></p>
<p>Adverse reactions, some of which are serious or fatal, can develop in patients who use MAOIs or who have recently been discontinued from an MAOI and started on a serotonergic antidepressant(s) or who have recently had SSRI or SNRI therapy discontinued prior to initiation of an MAOI <span class="Italics">[see <a href="#ID_d1775f86-090c-4b76-b46b-b330353f02ce">Dosage and Administration (2.4)</a>, <a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">Contraindications (4)</a> and <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>]</span>.</p>
<p><span class="Bold">Serotonergic Drugs</span></p>
<p>Based on the mechanism of action of BRINTELLIX and the potential for serotonin toxicity, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur when BRINTELLIX is coadministered with other drugs that may affect the serotonergic neurotransmitter systems (e.g., SSRIs, SNRIs, triptans, buspirone, tramadol, and tryptophan products etc.). Closely monitor symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> if BRINTELLIX is co-administered with other serotonergic drugs. Treatment with BRINTELLIX and any concomitant serotonergic agents should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> occurs <span class="Italics">[see <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>].</span></p>
<p><span class="Bold">Other CNS Active Agents </span></p>
<p>No clinically relevant effect was observed on steady state lithium exposure following coadministration with multiple daily doses of BRINTELLIX. Multiple doses of BRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam. A clinical study has shown that BRINTELLIX (single dose of 20 or 40 mg) did not increase the impairment of mental and motor skills caused by alcohol (single dose of 0.6 g/kg). Details on the potential <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between BRINTELLIX and bupropion can be found in <a href="#ID_29ade52b-7b35-43f2-92fb-be9205691a58">Section  7.3</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ba8fe8b4-40d1-4db3-84bc-a201614f1a43"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</h2>
<p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SSRIs and SNRIs are coadministered with warfarin.</p>
<p>Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of BRINTELLIX, no significant effects were observed in INR, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin <span class="Italics">[see <a href="#ID_50a0379d-1d8e-497c-83dd-a0db415ee3dc">Drug Interactions (7.4)</a>]</span>. Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid <span class="Italics">[see <a href="#ID_50a0379d-1d8e-497c-83dd-a0db415ee3dc">Drug Interactions (7.4)</a>]</span>. Patients receiving other drugs that interfere with hemostasis should be carefully monitored when BRINTELLIX is initiated or discontinued <span class="Italics">[see <a href="#ID_25158157-1a1c-41af-9cbe-90803d821e5c">Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_29ade52b-7b35-43f2-92fb-be9205691a58"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Potential for Other Drugs to Affect BRINTELLIX</h2>
<p class="First">Reduce BRINTELLIX dose by half when a strong CYP2D6 inhibitor (e.g., bupropion, fluoxetine, paroxetine, quinidine) is coadministered. Consider increasing the BRINTELLIX dose when a strong CYP inducer (e.g., rifampicin, carbamazepine, phenytoin) is coadministered. The maximum dose is not recommended to exceed three times the original dose <span class="Italics">[see <a href="#i4i_dosage_admin_id_e19d28bd-36a0-4d25-9ef8-fc0a0ee353c6">Dosage and Administration </a></span>(<span class="Italics"><a href="#ID_830b722e-0789-4361-b3b7-cfcab22ff69b">2.5</a> and <a href="#ID_a2804bb7-7f80-4ab1-9e40-0c8537bc0504">2.6)</a>] </span>(Figure 1).</p>
<p><span class="Bold">Figure 1. Impact of Other Drugs on Vortioxetine PK</span></p>
<div class="Figure">
<a name="id9467689"></a><img alt="Figure1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50a0379d-1d8e-497c-83dd-a0db415ee3dc"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Potential for BRINTELLIX to Affect Other Drugs</h2>
<p class="First">No dose adjustment for the comedications is needed when BRINTELLIX is coadministered with a substrate of CYP1A2 (e.g., duloxetine), CYP2A6, CYP2B6 (e.g., bupropion), CYP2C8 (e.g., repaglinide), CYP2C9 (e.g., S-warfarin), CYP2C19 (e.g., diazepam), CYP2D6 (e.g., venlafaxine), CYP3A4/5 (e.g., budesonide), and P-gp (e.g., digoxin). In addition, no dose adjustment for lithium, aspirin, and warfarin is necessary.</p>
<p>Vortioxetine and its metabolites are unlikely to inhibit the following CYP enzymes and transporter based on <span class="Italics">in vitro</span> data: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and P-gp. As such, no clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.</p>
<p>In addition, vortioxetine did not induce CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 in an <span class="Italics">in vitro </span>study in cultured human hepatocytes. Chronic administration of BRINTELLIX is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates <span class="Italics">(Figure 2).</span></p>
<p>Because vortioxetine is highly bound to plasma protein, coadministration of BRINTELLIX with another drug that is highly protein bound may increase free concentrations of the other drug. However, in a clinical study with coadministration of BRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein-bound drug, no significant change in INR was observed <span class="Italics">[see <a href="#ID_ba8fe8b4-40d1-4db3-84bc-a201614f1a43">Drug Interactions (7.2)</a>].</span></p>
<p><span class="Bold">Figure 2. Impact of Vortioxetine on PK of Other Drugs</span></p>
<div class="Figure">
<a name="id9467695"></a><img alt="Figure2.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_57f30d13-310d-48c6-b3fe-04aa66e4d1ae"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_7b00a858-52a4-43cd-825a-7bb8d77a08d9"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p><span class="Bold">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies of BRINTELLIX in pregnant women. Vortioxetine caused <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> when administered during pregnancy to rats and rabbits at doses 15 and 10 times the maximum recommended human dose (MRHD) of 20 mg, respectively. <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">Developmental delays</span> were also seen after birth in rats at doses 20 times the MRHD of vortioxetine given during pregnancy and through lactation. There were no teratogenic effects in rats or rabbits at doses up to 77 and 58 times, the MRHD of vortioxetine, respectively, given during organogenesis. The incidence of malformations in human pregnancies has not been established for BRINTELLIX. All human pregnancies, regardless of drug exposure, have a background rate of 2 to 4% for major malformations, and 15 to 20% for pregnancy loss. BRINTELLIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold">Clinical Considerations</span></p>
<p>Neonates exposed to SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of these classes of drugs or possibly, a drug discontinuation syndrome. It should be noted that in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2</a></span>)<span class="Italics">]</span>. When treating a pregnant woman with BRINTELLIX during the third trimester, the physician should carefully consider the potential risks and benefits of treatment<span class="Italics">.</span></p>
<p>Neonates exposed to SSRIs in pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN occurs in one to two per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI use in pregnancy and PPHN. Other studies do not show a significant statistical association.</p>
<p>A prospective longitudinal study was conducted of 201 pregnant women with a history of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> compared to those women who remained on antidepressant medication throughout pregnancy. When treating a pregnant woman with BRINTELLIX, the physician should carefully consider both the potential risks of taking a serotonergic antidepressant, along with the established benefits of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with an antidepressant.</p>
<p><span class="Bold">Animal Data</span></p>
<p>In pregnant rats and rabbits, no teratogenic effects were seen when vortioxetine was given during the period of organogenesis at oral doses up to 160 and 60 mg/kg/day, respectively. These doses are 77 and 58 times, in rats and rabbits, respectively, the maximum recommended human dose (MRHD) of 20 mg on a mg/m<span class="Sup">2  </span>basis. <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">Developmental delay</span>, seen as decreased fetal body weight and delayed ossification, occurred in rats and rabbits at doses equal to and greater than 30 and 10 mg/kg (15 and 10 times the MRHD, respectively) in the presence of maternal toxicity (decreased food consumption and decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>). When vortioxetine was administered to pregnant rats at oral doses up to 120 mg/kg (58 times the MRHD) throughout pregnancy and lactation, the number of live-born pups was decreased and early postnatal pup mortality was increased at 40 and 120 mg/kg. Additionally, pup weights were decreased at birth to weaning at 120 mg/kg and development (specifically eye opening) was slightly delayed at 40 and 120 mg/kg. These effects were not seen at 10 mg/kg (5 times the MRHD).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_491124cd-7dcc-436a-862a-c0961c784948"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether vortioxetine is present in human milk. Vortioxetine is present in the milk of lactating rats. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from BRINTELLIX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_916a2c92-71f0-4d3d-afef-92cecac25d9e"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Clinical studies on the use of BRINTELLIX in pediatric patients have not been conducted; therefore, the safety and effectiveness of BRINTELLIX in the pediatric population have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_cf4d5fd7-ddc3-42fb-ba73-6c23421b25ed"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No dose adjustment is recommended on the basis of age <span class="Italics">(Figure 3)</span>. Results from a single-dose pharmacokinetic study in elderly (&gt;65 years old) vs. young (24 to 45 years old) subjects demonstrated that the pharmacokinetics were generally similar between the two age groups.</p>
<p>Of the 2616 subjects in clinical studies of BRINTELLIX, 11% (286) were 65 and over, which included subjects from a placebo-controlled study specifically in elderly patients <span class="Italics">[see <a href="#i4i_clinical_studies_id_2b92635f-77ec-4a74-903a-362460333e59">Clinical Studies (14)</a>]</span>. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>Serotonergic antidepressants have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event <span class="Italics">[see <a href="#ID_cf1fdee0-361b-4c20-9f28-327182826a8e">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_edca85a9-6806-4fd8-b4ef-cab3c5643ffe"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Other Patient Populations</h2>
<p class="First">No dose adjustment of BRINTELLIX on the basis of race, gender, ethnicity, or renal function (from mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> to end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>) is necessary. In addition, the same dose can be administered in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">(Figure 3). </span>BRINTELLIX has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Therefore, BRINTELLIX is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Bold">Figure 3. Impact of Intrinsic Factors on Vortioxetine PK</span></p>
<div class="Figure">
<a name="id9467715"></a><img alt="Figure3.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-03.jpg">
</div>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_e9d9c7ee-fba2-4b11-814d-7f33a5f450b5"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">BRINTELLIX is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_321b340a-385d-4faf-a8f4-d77f3117fc18"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b9398b2e-1230-4c34-bc8b-24106c7f0ad8"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">There is limited clinical trial experience regarding human overdosage with BRINTELLIX. In pre-marketing clinical studies, cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> were limited to patients who accidentally or intentionally consumed up to a maximum dose of 40 mg of BRINTELLIX. The maximum single dose tested was 75 mg in men. Ingestion of BRINTELLIX in the dose range of 40 to 75 mg was associated with increased rates of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1c62f111-91ff-4f15-86b2-85fd044c8ab5"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">No specific antidotes for BRINTELLIX are known. In managing over dosage, consider the possibility of multiple drug involvement. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call Poison Control Center at 1-800-222-1222 for latest recommendations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_a708d399-23dd-4747-9074-645873880cc0"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BRINTELLIX is an immediate-release tablet for oral administration that contains the beta (Î²) polymorph of vortioxetine hydrobromide (HBr), an antidepressant. Vortioxetine HBr is known chemically as 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine, hydrobromide.Â The empirical formula is C<span class="Sub">18 </span>H<span class="Sub">22</span> N<span class="Sub">2</span> S, HBr with a molecular weight of 379.36 g/mol. The structural formula is:</p>
<div class="Figure">
<a name="id9467722"></a><img alt="chem structure.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-04.jpg">
</div>
<p>Vortioxetine HBr is a white to very slightly beige powder that is slightly soluble in water.</p>
<p>Each BRINTELLIX tablet contains 6.355 mg, 12.71 mg, 19.065 mg, or 25.42 mg of vortioxetine HBr equivalent to 5 mg, 10 mg, 15 mg, or 20 mg of vortioxetine, respectively. The inactive ingredients in BRINTELLIX tablets include mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate and film coating which consists of hypromellose, titanium dioxide, polyethylene glycol 400, iron oxide red (5 mg, 15 mg, and 20 mg) and iron oxide yellow (10 mg and 15 mg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_2fea7ae4-ae4e-41ff-a04d-ed0a2c2e8a12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_1b63f969-6ec2-4502-90cb-57fda73e57c7"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of the antidepressant effect of vortioxetine is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to vortioxetineâ€™s antidepressant effect has not been established.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_b85fdbba-5c91-4f3d-a238-a247021de183"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Vortioxetine binds with high affinity to the human serotonin transporter (Ki=1.6 nM), but not to the norepinephrine (Ki=113 nM) or dopamine (Ki&gt;1000 nM) transporters. Vortioxetine potently and selectively inhibits reuptake of serotonin (IC50=5.4 nM). Vortioxetine binds to 5-HT3 (Ki=3.7 nM), 5-HT1A (Ki=15 nM), 5-HT7 (Ki=19 nM), 5-HT1D (Ki=54 nM), and 5-HT1B (Ki=33 nM), receptors and is a 5-HT3, 5-HT1D, and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor agonist.</p>
<p>In humans, the mean 5-HT transporter occupancy, based on the results from 2 clinical PET studies using 5-HTT ligands ([<span class="Sup">11</span>C]-MADAM or [<span class="Sup">11</span>C]-DASB), was approximately 50% at 5 mg/day, 65% at 10 mg/day and approximately 80% at 20 mg/day in the regions of interest.</p>
<p><span class="Bold">Effect on Cardiac Repolarization</span></p>
<p>The effect of vortioxetine 10 mg and 40 mg administered once daily on QTc interval was evaluated in a randomized, double-blind, placebo-, and active-controlled (moxifloxacin 400 mg), four-treatment-arm parallel study in 340 male subjects. In the study the upper bound of the one-sided 95% confidence interval for the QTc was below 10 ms, the threshold for regulatory concern. The oral dose of 40 mg is sufficient to assess the effect of metabolic inhibition.</p>
<p><span class="Bold">Effect on Driving Performance</span></p>
<p>In a clinical study in healthy subjects, BRINTELLIX did not impair driving performance, or have adverse psychomotor or cognitive effects following single and multiple doses of 10 mg/day. Because any psychoactive drug may impair judgment, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that BRINTELLIX therapy does not affect their ability to engage in such activities.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_6a3ebda0-245d-4a60-9b5f-6970522ec906"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Vortioxetine pharmacological activity is due to the parent drug. The pharmacokinetics of vortioxetine (2.5 mg to 60 mg) are linear and dose-proportional when vortioxetine is administered once daily. The mean terminal half-life is approximately 66 hours, and steady-state plasma concentrations are typically achieved within two weeks of dosing.</p>
<p><span class="Bold">Absorption</span></p>
<p>The maximal plasma vortioxetine concentration (C<span class="Sub">max</span>) after dosing is reached within 7 to 11 hours postdose (T<span class="Sub">max</span>). Steady-state mean C<span class="Sub">max</span> values were 9, 18, and 33 ng/mL following doses of 5, 10, and 20 mg/day. Absolute bioavailability is 75%. No effect of food on the pharmacokinetics was observed.</p>
<p><span class="Bold">Distribution</span></p>
<p>The apparent volume of distribution of vortioxetine is approximately 2600Â L, indicating extensive extravascular distribution. The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations. No apparent difference in the plasma protein binding between healthy subjects and subjects with hepatic (mild, moderate) or renal (mild, moderate, severe, ESRD) impairment is observed.</p>
<p><span class="Bold">Metabolism and Elimination</span></p>
<p>Vortioxetine is extensively metabolized primarily through oxidation via cytochrome P450 isozymes CYP2D6, CYP3A4/5,Â CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 and subsequent glucuronic acid conjugation. CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine to its major, pharmacologically inactive, carboxylic acid metabolite, and poor metabolizers of CYP2D6 have approximately twice the vortioxetine plasma concentration of extensive metabolizers.</p>
<p>Following a single oral dose of [<span class="Sup">14</span>C]-labeled vortioxetine, approximately 59% and 26% of the administered radioactivity was recovered in the urine and feces, respectively as metabolites. Negligible amounts of unchanged vortioxetine were excreted in the urine up to 48 hours. The presence of hepatic (mild or moderate) or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (mild, moderate, severe and ESRD) did not affect the apparent clearance of vortioxetine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_33d66a16-7eac-46ad-9ec1-fc627b3116cb"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_bc5128f0-8b53-44f3-8ffb-64afe0d0d81c"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Carcinogenicity studies were conducted in which CD-1 mice and Wistar rats were given oral doses of vortioxetine up to 50 and 100 mg/kg/day for male and female mice, respectively, and 40 and 80 mg/kg/day for male and female rats, respectively, for 2 years. The doses in the two species were approximately 12, 24, 20, and 39 times, respectively, the maximum recommended human dose (MRHD) of 20 mg on a mg/m<span class="Sup">2</span> basis.</p>
<p>In rats, the incidence of benign polypoid <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the rectum was statistically significantly increased in females at doses 39 times the MRHD, but not at 15 times the MRHD. These were considered related to <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and possibly caused by an interaction with a vehicle component of the formulation used for the study. The finding did not occur in male rats at 20 times the MRHD.</p>
<p>In mice, vortioxetine was not carcinogenic in males or females at doses up to 12 and 24 times, respectively, the MRHD.</p>
<p><span class="Bold">Mutagenicity</span></p>
<p>Vortioxetine was not genotoxic in the <span class="Italics">in vitro</span> bacterial reverse mutation assay (Ames test), an <span class="Italics">in vitro</span> chromosome aberration assay in cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and an <span class="Italics">in vivo</span> rat bone marrow micronucleus assay.</p>
<p><span class="Bold">Impairment of Fertility</span></p>
<p>Treatment of rats with vortioxetine at doses up to 120 mg/kg/day had no effect on male or female fertility, which is 58 times the maximum recommended human dose (MRHD) of 20 mg on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_2b92635f-77ec-4a74-903a-362460333e59"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of BRINTELLIX in treatment for MDD was established in six 6 to 8 week randomized, double-blind, placebo-controlled, fixed-dose studies (including one study in the elderly) and one maintenance study in adult inpatients and outpatients who met the Diagnostic and Statistical Manual of <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Mental Disorders</span> (DSM-IV-TR) criteria for MDD.  </p>
<p><span class="Bold">Adults (aged 18 years to 75 years)</span></p>
<p>The efficacy of BRINTELLIX in patients aged 18 years to 75 years was demonstrated in five 6 to 8 week, placebo-controlled studies (Studies 1 to 5 in <span class="Italics">Table 4</span>). In these studies, patients were randomized to BRINTELLIX 5 mg, 10 mg, 15 mg or 20 mg or placebo once daily. For patients who were randomized to BRINTELLIX 15 mg/day or 20 mg/day, the final doses were titrated up from 10 mg/day after the first week.</p>
<p>The primary efficacy measures were the Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Scale (HAMD-24) total score in Study 2 and the Montgomery-Asberg <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (MADRS) total score in all other studies. In each of these studies, at least one dose group of BRINTELLIX was superior to placebo in improvement of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> as measured by mean change from baseline to endpoint visit on the primary efficacy measurement <span class="Italics">(see Table 4)</span>. Subgroup analysis by age, gender or race did not suggest any clear evidence of differential responsiveness. Two studies of the 5 mg dose in the U.S. (not represented in <span class="Italics">Table </span>4) failed to show effectiveness.</p>
<p><span class="Bold">Elderly Study (aged 64 years to 88 years)</span></p>
<p>The efficacy of BRINTELLIX for the treatment of MDD was also demonstrated in a randomized, double-blind, placebo-controlled, fixed-dose study of BRINTELLIX in elderly patients (aged 64 years to 88 years) with MDD (Study 6 in <span class="Italics">Table 4</span>). Patients meeting the diagnostic criteria for recurrent MDD with at least one previous major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> before the age of 60 years and without comorbid <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (Mini Mental State Examination score &lt;24) received BRINTELLIX 5 mg or placebo.</p>
<table width="100%">
<col width="13%">
<col width="27%">
<col width="10%">
<col width="12%">
<col width="15%">
<col width="22%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Difference (drug minus placebo) in least-squares mean change from baseline.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">â€ </a></dt>
<dd>Doses that are statistically significantly superior to placebo after adjusting for multiplicity.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" colspan="6"><p class="First"><span class="Bold">Table 4. Primary Efficacy Results of 6 Week to 8 Week Clinical Trials</span></p></td></tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">Study No.</span><br><span class="Bold">[Primary</span><br><span class="Bold">Measure]</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Treatment Group</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Number</span><br><span class="Bold">of</span><br><span class="Bold">Patients</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Mean</span><br><span class="Bold">Baseline</span><br><span class="Bold">Score (SD)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">LS Mean</span><br><span class="Bold">Change from</span><br><span class="Bold">Baseline (SE)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Placebo</span>-<span class="Bold">subtracted</span><br><span class="Bold">Difference</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><span class="Bold">(95% CI)</span></p></td>
</tr>
<tr>
<td class="Botrule" rowspan="3"><p class="First">Study 1<br>[MADRS]<br>Non-US<br>Study</p></td>
<td><p class="First">BRINTELLIX (5 mg/day)<a name="footnote-reference-5" href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">108</p></td>
<td align="center"><p class="First">34.1 (2.6)</p></td>
<td align="center"><p class="First">-20.4 (1.0)</p></td>
<td align="center"><p class="First">-5.9 (-8.6, -3.2)</p></td>
</tr>
<tr>
<td><p class="First">BRINTELLIX (10 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">100</p></td>
<td align="center"><p class="First">34.0 (2.8)</p></td>
<td align="center"><p class="First">-20.2 (1.0)</p></td>
<td align="center"><p class="First">-5.7 (-8.5, -2.9)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Placebo</p></td>
<td class="Botrule" align="center"><p class="First">105</p></td>
<td class="Botrule" align="center"><p class="First">33.9 (2.7)</p></td>
<td class="Botrule" align="center"><p class="First">-14.5 (1.0)</p></td>
<td class="Botrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td rowspan="3"><p class="First">Study 2<br>[HAMD-24]<br>Non-US<br>Study</p></td>
<td><p class="First">BRINTELLIX (5 mg/day)</p></td>
<td align="center"><p class="First">139</p></td>
<td align="center"><p class="First">32.2 (5.0)</p></td>
<td align="center"><p class="First">-15.4 (0.7)</p></td>
<td align="center"><p class="First">-4.1 (-6.2, -2.1)</p></td>
</tr>
<tr>
<td><p class="First">BRINTELLIX (10 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">139</p></td>
<td align="center"><p class="First">33.1 (4.8)</p></td>
<td align="center"><p class="First">-16.2 (0.8)</p></td>
<td align="center"><p class="First">-4.9 (-7.0, -2.9)</p></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">139</p></td>
<td align="center"><p class="First">32.7 (4.4)</p></td>
<td align="center"><p class="First">-11.3 (0.7)</p></td>
<td align="center"><p class="First">--</p></td>
</tr>
<tr>
<td rowspan="3"><p class="First">Study 3<br>[MADRS]<br>Non-US<br>Study</p></td>
<td><p class="First">BRINTELLIX (15 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">149</p></td>
<td align="center"><p class="First">31.8 (3.4)</p></td>
<td align="center"><p class="First">-17.2 (0.8)</p></td>
<td align="center"><p class="First">-5.5 (-7.7, -3.4)</p></td>
</tr>
<tr>
<td><p class="First">BRINTELLIX (20 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">151</p></td>
<td align="center"><p class="First">31.2 (3.4)</p></td>
<td align="center"><p class="First">-18.8 (0.8)</p></td>
<td align="center"><p class="First">-7.1 (-9.2, -5.0)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Placebo</p></td>
<td class="Botrule" align="center"><p class="First">158</p></td>
<td class="Botrule" align="center"><p class="First">31.5 (3.6)</p></td>
<td class="Botrule" align="center"><p class="First">-11.7 (0.8)</p></td>
<td class="Botrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td rowspan="3"><p class="First">Study 4<br>[MADRS]<br>US Study</p></td>
<td><p class="First">BRINTELLIX (15 mg/day)</p></td>
<td align="center"><p class="First">145</p></td>
<td align="center"><p class="First">31.9 (4.1)</p></td>
<td align="center"><p class="First">-14.3 (0.9)</p></td>
<td align="center"><p class="First">-1.5 (-3.9, 0.9)</p></td>
</tr>
<tr>
<td><p class="First">BRINTELLIX (20 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">147</p></td>
<td align="center"><p class="First">32.0 (4.4)</p></td>
<td align="center"><p class="First">-15.6 (0.9)</p></td>
<td align="center"><p class="First">-2.8 (-5.1, -0.4)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Placebo</p></td>
<td class="Botrule" align="center"><p class="First">153</p></td>
<td class="Botrule" align="center"><p class="First">31.5 (4.2)</p></td>
<td class="Botrule" align="center"><p class="First">-12.8 (0.8)</p></td>
<td class="Botrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td rowspan="3"><p class="First">Study 5<br>[MADRS]<br>US Study</p></td>
<td><p class="First">BRINTELLIX (10 mg/day)</p></td>
<td align="center"><p class="First">154</p></td>
<td align="center"><p class="First">32.2 (4.5)</p></td>
<td align="center"><p class="First">-13.0 (0.8)</p></td>
<td align="center"><p class="First">-2.2 (-4.5, 0.1)</p></td>
</tr>
<tr>
<td><p class="First">BRINTELLIX (20 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">148</p></td>
<td align="center"><p class="First">32.5 (4.3)</p></td>
<td align="center"><p class="First">-14.4 (0.9)</p></td>
<td align="center"><p class="First">-3.6 (-5.9, -1.4)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Placebo</p></td>
<td class="Botrule" align="center"><p class="First">155</p></td>
<td class="Botrule" align="center"><p class="First">32.0 (4.0)</p></td>
<td class="Botrule" align="center"><p class="First">-10.8 (0.8)</p></td>
<td class="Botrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td rowspan="2"><p class="First">Study 6<br>(elderly)<br>[HAMD-24]<br>US and<br>Non-US </p></td>
<td><p class="First">BRINTELLIX (5 mg/day)<a href="#footnote-5" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">155</p></td>
<td align="center"><p class="First">29.2 (5.0)</p></td>
<td align="center"><p class="First">-13.7 (0.7)</p></td>
<td align="center"><p class="First">-3.3 (-5.3, -1.3)</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Placebo</p></td>
<td class="Botrule" align="center"><p class="First">145</p></td>
<td class="Botrule" align="center"><p class="First">29.4 (5.1)</p></td>
<td class="Botrule" align="center"><p class="First">-10.3 (0.8)</p></td>
<td class="Botrule" align="center"><p class="First">--</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="6"><p class="First">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</p></td></tr>
</tbody>
</table>
<p><span class="Bold">Time Course of Treatment Response</span></p>
<p>In the 6 to 8 week placebo-controlled studies, an effect of BRINTELLIX based on the primary efficacy measure was generally observed starting at Week 2 and increased in subsequent weeks with the full antidepressant effect of BRINTELLIX generally not seen until Study Week 4 or later. <span class="Italics">Figure </span>4 depicts time course of response in U.S. based on the primary efficacy measure (MADRS) in Study 5.</p>
<p><span class="Bold">Figure 4. Change from Baseline in MADRS Total Score by Study Visit (Week) in Study 5</span></p>
<div class="Figure">
<a name="id4584805"></a><img alt="Figure4.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-05.jpg">
</div>
<p><span class="Bold">Figure 5. Difference from Placebo in Mean Change from Baseline in MADRS Total Score at Week 6 or Week 8</span></p>
<div class="Figure">
<a name="id9468334"></a><img alt="Figure5.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-06.jpg">
</div>
<dl>
<dt>Â </dt>
<dd>â€ Results (point estimate and unadjusted 95% confidence interval) are from mixed model for repeated measures (MMRM) analysis. In Studies 1 and 6, the primary analysis was not based on MMRM and in Studies 2 and 6 the primary efficacy measure was not based on MADRS.</dd>
</dl>
<p><span class="Bold">Maintenance Study</span></p>
<p>In a non-US maintenance study (Study 7 <span class="Italics">in Figure 6</span>), 639 patients meeting DSM-IV-TR criteria for MDD received flexible doses of BRINTELLIX (5 mg or 10 mg) once daily during an initial 12 week open-label treatment phase; the dose of BRINTELLIX was fixed during Weeks 8 to 12. Three hundred ninety six (396) patients who were in remission (MADRS total score â‰¤10 at both Weeks 10 and 12) after open-label treatment were randomly assigned to continuation of a fixed dose of BRINTELLIX at the final dose they responded to (about 75% of patients were on 10 mg/day) during the open-label phase or to placebo for 24 to 64 weeks. Approximately 61% of randomized patients satisfied remission criterion (MADRS total score â‰¤10) for at least 4 weeks (since Week 8), and 15% for at least 8 weeks (since Week 4). Patients on BRINTELLIX experienced a statistically significantly longer time to have recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> than did patients on placebo. Recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> was defined as a MADRS total score â‰¥22 or lack of efficacy as judged by the investigator.</p>
<p><span class="Bold">Figure 6. Kaplan-Meier Estimates of Proportion of Patients with Recurrence (Study 7)</span></p>
<div class="Figure">
<a name="id4585024"></a><img alt="Figure6.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_0a922490-340f-4a07-828f-42aa2358f396"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BRINTELLIX tablets are available as follows:</p>
<table width="100%">
<col width="13%">
<col width="22%">
<col width="22%">
<col width="22%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Features</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Strengths</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">5 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">10 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">15 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">20 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Color</p></td>
<td class="Botrule Lrule Rrule"><p class="First">pink</p></td>
<td class="Botrule Lrule Rrule"><p class="First">yellow</p></td>
<td class="Botrule Lrule Rrule"><p class="First">orange</p></td>
<td class="Botrule Lrule Rrule"><p class="First">red</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Debossment</p></td>
<td class="Botrule Lrule Rrule"><p class="First">â€œ5â€? on one side of tablet<br>â€œTLâ€? on other side of tablet</p></td>
<td class="Botrule Lrule Rrule"><p class="First">â€œ10â€? on one side of tablet<br>â€œTLâ€? on other side of tablet</p></td>
<td class="Botrule Lrule Rrule"><p class="First">â€œ15â€? on one side of tablet<br>â€œTLâ€? on other side of tablet</p></td>
<td class="Botrule Lrule Rrule"><p class="First">â€œ20â€? on one side of tablet<br>â€œTLâ€? on other side of tablet</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Presentations and NDC Codes</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Bottles of 30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-550-30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-560-30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-570-30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-580-30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Bottles of 90</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-550-90</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-560-90</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-570-90</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-580-90</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Bottles of 500</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-550-77</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-560-77</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-570-77</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64764-580-77</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Storage:</span> Store at 77Â°F (25Â°C); excursions permitted to 59Â°F to 86Â°F (15Â°C to 30Â°C) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_07e9eca5-3922-4068-9d0a-d8290811463f"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide)</p>
<p>Advise patients and their caregivers about the benefits and risks associated with treatment with BRINTELLIX and counsel them in its appropriate use. Advise patients and their caregivers to read the Medication Guide and assist them in understanding its contents. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</span></p>
<p>Advise patients and caregivers to look for the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior, especially early during treatment and when the dose is adjusted up or down <span class="Italics">[see <a href="#_RefID_842f20ae-e2f0-4419-a495-485ef2e9d">Boxed Warning</a> and <a href="#ID_acb6b79c-6549-4e5d-88da-a3542e95d85d">Warnings and Precautions (5.1)</a>]</span>.</p>
<p><span class="Bold">Discontinuation of Treatment </span></p>
<p>Patients who are on BRINTELLIX 15 mg/day or 20 mg/day may experience <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, muscle <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, sudden outburst of <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> if they abruptly stop their medicine. Advise patients not stopping BRINTELLIX without talking to their healthcare provider <span class="Italics">[see <a href="#i4i_adverse_effects_id_8ac33d8e-c6a8-493a-9d94-7ceffa98817a">Adverse Reactions (6)</a>].</span></p>
<p><span class="Bold">Concomitant Medication </span></p>
<p>Advise patients to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter medications because of a potential for interactions. Instruct patients not to take BRINTELLIX with an MAOI or within 14 days of stopping an MAOI and to allow 21 days after stopping BRINTELLIX before starting an MAOI <span class="Italics">[see <a href="#ID_d1775f86-090c-4b76-b46b-b330353f02ce">Dosage and Administration (2.4)</a>, <a href="#i4i_contraindications_id_fab8a926-4eb9-4363-be81-d8417138c01e">Contraindications (4)</a>, <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a>, and <a href="#ID_0838e3d5-2a24-419d-bff0-13cbd5db39fb">Drug Interactions (7.1)</a>]</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></p>
<p>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly with the concomitant use of BRINTELLIX and triptans, tricyclic antidepressants, fentanyl, Lithium, tramadol, tryptophan supplements, and St. Johnâ€™s Wort supplements <span class="Italics">[see <a href="#ID_0e16b5b0-4ad5-4cb0-9610-aaa272afec0c">Warnings and Precautions (5.2)</a> and <a href="#ID_0838e3d5-2a24-419d-bff0-13cbd5db39fb">Drug Interactions (7.1, 7.2)</a>]</span>.</p>
<p><span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p>Caution patients about the increased risk of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when BRINTELLIX is given with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation <span class="Italics">[see <a href="#ID_25158157-1a1c-41af-9cbe-90803d821e5c">Warnings and Precautions (5.3)</a>]</span>.</p>
<p><span class="Bold">Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></span></p>
<p>Advise patients and their caregivers to look for signs of activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> <span class="Italics">[see <a href="#ID_fd0c522f-7828-4663-a0b5-f31387756659">Warnings and Precautions (5.4)</a>]</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span></span></p>
<p>Patients should be advised that taking BRINTELLIX can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>.  Pre-existing <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is almost always open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> because <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>, when diagnosed, can be treated definitively with iridectomy.  Open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is not a risk factor for <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>.  Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> procedure (e.g., iridectomy), if they are susceptible <span class="Italics">[see <a href="#i4i_warnings_precautions_id_0e6d4856-3681-40d7-9383-d370de9e7af7">Warnings and Precautions</a> (<a href="#ID_4f336d1f-a6d7-4042-bde3-a65345475cc0">5.5</a>)]</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></span></p>
<p>Advise patients that if they are treated with diuretics, or are otherwise volume depleted, or are elderly, they may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> while taking BRINTELLIX <span class="Italics">[see <a href="#ID_cf1fdee0-361b-4c20-9f28-327182826a8e">Warnings and Precautions (5.6)</a>]</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></p>
<p>Advise patients that <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> is the most common adverse reaction, and is dose related. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> commonly occurs within the first week of treatment, then decreases in frequency but can persist in some patients.</p>
<p><span class="Bold">Alcohol</span></p>
<p>A clinical study has shown that BRINTELLIX (single dose of 20 or 40 mg/day) did not increase the impairment of mental and motor skills caused by alcohol.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Advise patients to notify their healthcare provider if they develop an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.</p>
<p><span class="Bold">Pregnancy </span></p>
<p>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during therapy with BRINTELLIX <span class="Italics">[see <a href="#ID_7b00a858-52a4-43cd-825a-7bb8d77a08d9">Use in Specific Populations (8.1)</a>]</span>.</p>
<p><span class="Bold">Nursing Mothers </span></p>
<p>Advise patients to notify their healthcare provider if they are breast-feeding an infant and would like to continue or start BRINTELLIX <span class="Italics">[see <a href="#ID_491124cd-7dcc-436a-862a-c0961c784948">Use in Specific Populations (8.3)</a>]</span>.</p>
<p>Distributed and marketed by:</p>
<p><span class="Bold">Takeda Pharmaceuticals America, Inc.</span></p>
<p>Deerfield, IL 60015</p>
<p>Marketed by:</p>
<p><span class="Bold">Lundbeck</span></p>
<p>Deerfield, IL 60015</p>
<p>BRINTELLIX is a trademark of H. Lundbeck A/S registered with the U.S Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>Â©2013, 2014 Takeda Pharmaceuticals America, Inc.</p>
<p>LUN205 R4 July 2014</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_aa4ebc39-7a51-42fc-8694-f66614f84fc7"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">BRINTELLIX [brinâ€™-tel-ix]</span></p>
<p><span class="Bold">(vortioxetine) Tablets</span></p>
<p>Read this Medication Guide before you start taking BRINTELLIX and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about BRINTELLIX?</span></p>
<p><span class="Bold">BRINTELLIX and other antidepressant medicines may cause serious side effects.</span></p>
<dl>
<dt>1.</dt>
<dd><span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or youngÂ adults within theÂ first few months of treatment.</span></dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. </span>These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.</dd>
<dt>3.</dt>
<dd><span class="Bold">How can I watch for and try to prevent suicidal thoughts and actions?</span></dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</dd>
<dt>â€¢</dt>
<dd>Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</dd>
<dt>â€¢</dt>
<dd>Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.</dd>
</dl>
<p><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<table width="100%">
<col width="47%">
<col width="53%">
<tbody class="Headless">
<tr class="First Toprule">
<td><dl>
<dt>â€¢</dt>
<dd>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></dd>
</dl></td>
<td><dl>
<dt>â€¢</dt>
<dd>trouble sleeping</dd>
</dl></td>
</tr>
<tr>
<td><dl>
<dt>â€¢</dt>
<dd>acting on dangerous impulses</dd>
</dl></td>
<td><dl>
<dt>â€¢</dt>
<dd>an extreme increase in activity or talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</dd>
</dl></td>
</tr>
<tr>
<td><dl>
<dt>â€¢</dt>
<dd>acting aggressive, being angry or violent</dd>
</dl></td>
<td><dl>
<dt>â€¢</dt>
<dd>other unusual changes in behavior or mood</dd>
</dl></td>
</tr>
<tr>
<td><dl>
<dt>â€¢</dt>
<dd>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</dd>
</dl></td>
<td><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></dd>
</dl></td>
</tr>
<tr>
<td><dl>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
</dl></td>
<td><dl>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></dd>
</dl></td>
</tr>
<tr>
<td><dl>
<dt>â€¢</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></dd>
</dl></td>
<td></td>
</tr>
<tr class="Botrule Last">
<td><dl>
<dt>â€¢</dt>
<dd>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, angry or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span></dd>
</dl></td>
<td></td>
</tr>
</tbody>
</table>
<p><span class="Bold">What is BRINTELLIX? </span></p>
<p>BRINTELLIX is a prescription medicine used to treat a certain type of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> called Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD). </p>
<p>It is important to talk with your healthcare provider about the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risk of not treating it. You should discuss all treatment choices with your healthcare provider.</p>
<dl>
<dt>â€¢</dt>
<dd>Talk to your healthcare provider if you do not think that your condition is getting better with BRINTELLIX treatment.</dd>
</dl>
<p><span class="Bold">Who should not take BRINTELLIX? </span></p>
<p><span class="Bold">Do not take BRINTELLIX if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to vortioxetine, or any of the ingredients in BRINTELLIX. See the end of this Medication Guide for a complete list of ingredients in BRINTELLIX.</dd>
<dt>â€¢</dt>
<dd>take a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.</dd>
<dt>â€¢</dt>
<dd>Do not take an MAOI within 21 days of stopping BRINTELLIX.</dd>
<dt>â€¢</dt>
<dd>Do not start BRINTELLIX if you stopped taking an MAOI in the last 14 days.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking BRINTELLIX? </span></p>
<p><span class="Bold">Tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have liver problems</dd>
<dt>â€¢</dt>
<dd>have or had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or bipolar disorder (<span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">manic depression</span>)</dd>
<dt>â€¢</dt>
<dd>have low salt (sodium) levels in your blood</dd>
<dt>â€¢</dt>
<dd>have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</dd>
<dt>â€¢</dt>
<dd>drink alcohol</dd>
<dt>â€¢</dt>
<dd>have any other medical conditions</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. It is not known if BRINTELLIX will harm your unborn baby.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if BRINTELLIX passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRINTELLIX.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines that you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements. BRINTELLIX and some medicines may interact with each other, may not work as well, or may cause serious side effects when taken together.</p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<dl>
<dt>â€¢</dt>
<dd>medicines used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> (e.g. triptans)</dd>
<dt>â€¢</dt>
<dd>medicines used to treat mood, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or thought disorders, including tricyclics, lithium, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), buspirone, or antipsychotics</dd>
<dt>â€¢</dt>
<dd>MAOIs (including linezolid, an antibiotic)</dd>
<dt>â€¢</dt>
<dd>Tramadol or fentanyl</dd>
<dt>â€¢</dt>
<dd>over-the-counter supplements such as tryptophan or St. Johnâ€™s Wort</dd>
<dt>â€¢</dt>
<dd>nonsteroidal anti-inflammatory drugs (NSAIDs)</dd>
<dt>â€¢</dt>
<dd>aspirin</dd>
<dt>â€¢</dt>
<dd>warfarin (Coumadin, Jantoven)</dd>
<dt>â€¢</dt>
<dd>diuretics</dd>
<dt>â€¢</dt>
<dd>rifampicin</dd>
<dt>â€¢</dt>
<dd>carbamazepine</dd>
<dt>â€¢</dt>
<dd>phenytoin</dd>
<dt>â€¢</dt>
<dd>quinidine</dd>
</dl>
<p>Ask your healthcare provider if you are not sure if you are taking any of these medicines.</p>
<p>Before you take BRINTELLIX with any of these medicines, talk to your healthcare provider about <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. See â€œWhat are the possible side effects of BRINTELLIX?â€?</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.</p>
<p><span class="Bold">How should I take BRINTELLIX?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take BRINTELLIX exactly as your healthcare provider tells you to take it.</dd>
<dt>â€¢</dt>
<dd>Take BRINTELLIX at about the same time each day. </dd>
<dt>â€¢</dt>
<dd>Your healthcare provider may need to change the dose of BRINTELLIX until it is the right dose for you.</dd>
<dt>â€¢</dt>
<dd>Do not start or stop taking BRINTELLIX without talking to your healthcare provider first. Suddenly stopping BRINTELLIX when you take higher doses may cause you to have side effects, including:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd>stiff muscles</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span></dd>
<dt>â€¢</dt>
<dd>sudden outburst of <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or feeling lightheaded</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span></dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>BRINTELLIX may be taken with or without food.</dd>
<dt>â€¢</dt>
<dd>If you take too much BRINTELLIX, call the Poison Control Center at 1-800-222-1222 or go to the nearest hospital emergency room right away.</dd>
</dl>
<p><span class="Bold">What should I avoid while taking BRINTELLIX? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Do not drive, operate heavy machinery, or do other dangerous activities until you know how BRINTELLIX affects you.</dd>
<dt>â€¢</dt>
<dd>Avoid drinking alcohol while taking BRINTELLIX.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of BRINTELLIX? </span></p>
<p><span class="Bold">BRINTELLIX may cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">See â€œWhat is the most important information I should know about BRINTELLIX?â€?</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. </span>A potentially life-threatening problem called <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> can happen when medicines such as BRINTELLIX are taken with certain other medicines. Symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may include:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or other changes in mental status</dd>
<dt>â€¢</dt>
<dd>problems controlling your movements or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span></dd>
<dt>â€¢</dt>
<dd>fast heartbeat</dd>
<dt>â€¢</dt>
<dd>high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span> or tightness</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>. </span>BRINTELLIX may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, especially if you take the blood thinner warfarin (CoumadinÂ®, JantovenÂ®), a non-steroidal anti-inflammatory drug (NSAID), or aspirin.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span></span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span>). Symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> include:<dl>
<dt>â€¢</dt>
<dd>greatly increased energy</dd>
<dt>â€¢</dt>
<dd>severe problems sleeping</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span></dd>
<dt>â€¢</dt>
<dd>reckless behavior</dd>
<dt>â€¢</dt>
<dd>unusually grand ideas</dd>
<dt>â€¢</dt>
<dd>excessive happiness or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></dd>
<dt>â€¢</dt>
<dd>talking more or faster than usual</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">visual problems</span><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></dd>
<dt>â€¢</dt>
<dd>changes in vision</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in or around the eye</dd>
</dl>
</dd>
</dl>
<p>Only some people are at risk for these problems.  You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">low levels of salt (sodium) in your blood.</span> Symptoms of this may include: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, memory changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span> on your feet. Symptoms of severe or sudden cases of low salt levels in your blood may include: <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not real), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. If not treated, severe low sodium levels can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</dd>
</dl>
<p>Common side effects in people who take BRINTELLIX include:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of BRINTELLIX. For more information, ask your healthcare provider or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store BRINTELLIX? </span></p>
<p>Store BRINTELLIX at room temperature between 59Â°F to 86Â°F (15Â°C to 30Â°C).</p>
<p><span class="Bold">Keep BRINTELLIX and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of BRINTELLIX.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BRINTELLIX for a condition for which it was not prescribed. Do not give BRINTELLIX to other people, even if they have the same condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about BRINTELLIX. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about BRINTELLIX that is written for healthcare professionals.</p>
<p>For more information, go to <a href="http://www.BRINTELLIX.com">www.BRINTELLIX.com</a> or call 1-877-TAKEDA-7 (1-877-825-3327).</p>
<p><span class="Bold">What are the ingredients in BRINTELLIX? </span></p>
<p>Active ingredient: vortioxetine hydrobromide</p>
<p>Inactive ingredients: mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate and film coating consisting of hypromellose, titanium dioxide, polyethylene glycol 400, iron oxide red (5 mg, 15 mg, and 20 mg) and iron oxide yellow (10 mg and 15 mg)</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Distributed and Marketed by:</p>
<p><span class="Bold">Takeda Pharmaceuticals America, Inc.</span></p>
<p>Deerfield, IL 60015</p>
<p>Marketed by:</p>
<p><span class="Bold">Lundbeck</span></p>
<p>Deerfield, IL 60015</p>
<p>BRINTELLIX is a trademark of H. Lundbeck A/S registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>All other trademarks are the property of their respective owners.</p>
<p>Â©2013, 2014 Takeda Pharmaceuticals America, Inc.</p>
<p>LUN205 R4 July 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_cf28b69f-9ed2-4f9c-ae74-b7c9eae4097b"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Package Display Panel-5 mg 30 count Bottle</span></p>
<p>NDC 64764-550-30<br>30 Tablets<br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Brintellix</span><br>vortioxetine<br>tablets<br>5 mg*</p>
<p><span class="Bold">Attention: Dispense with the<br>accompanying Medication Guide.</span></p>
<p><span class="Italics">Takeda logo</span><br><span class="Italics">Lundbeck logo</span></p>
<p>Lot</p>
<p>Exp.</p>
<p>Product of</p>
<p>L244-02</p>
<p>*Each pink tablet contains: 6.355 mg vortioxetine hydrobromide (equivalent<br>to 5 mg vortioxetine).<br>Dist. and Mktd. by: <span class="Bold">Takeda Pharmaceuticals America, Inc.,</span> Deerfield, IL 60015<br>Mktd. by: <span class="Bold">Lundbeck,</span> Deerfield, IL 60015<br>BRINTELLIX is a trademark of H. Lundbeck A/S and is used under license by<br>Takeda Pharmaceuticals America, Inc.</p>
<p>Tamper-evident: Do not accept if seal over bottle opening is broken or missing.<br>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP<br>Controlled Room Temperature].<br><span class="Bold">Usual Dosage:</span> See package insert.</p>
<p><span class="Italics">barcode</span></p>
<div class="Figure">
<a name="id20795116"></a><img alt="5mg-30ct.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5146f116-3271-4933-93c9-ff1dd4116108"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Package Display Panel-10 mg 30 count Bottle</span></p>
<p>NDC 64764-560-30<br>30 Tablets<br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Brintellix</span><br>vortioxetine<br>tablets<br>10 mg*</p>
<p><span class="Bold">Attention: Dispense with the<br>accompanying Medication Guide.</span></p>
<p><span class="Italics">Takeda logo</span><br><span class="Italics">Lundbeck logo</span></p>
<p>Lot</p>
<p>Exp.</p>
<p>Product of</p>
<p>L248-02</p>
<p>*Each yellow tablet contains: 12.71 mg vortioxetine hydrobromide (equivalent<br>to 10 mg vortioxetine).<br>Dist. and Mktd. by: <span class="Bold">Takeda Pharmaceuticals America, Inc.,</span> Deerfield, IL 60015<br>Mktd. by: <span class="Bold">Lundbeck,</span> Deerfield, IL 60015<br>BRINTELLIX is a trademark of H. Lundbeck A/S registered with the U.S Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>Tamper-evident: Do not accept if seal over bottle opening is broken or missing.<br>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP<br>Controlled Room Temperature].<br><span class="Bold">Usual Dosage:</span> See package insert.</p>
<p><span class="Italics">barcode</span></p>
<div class="Figure">
<a name="id20795121"></a><img alt="10mg-30ct.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_b861f598-21ac-4019-9678-853b1b25c282"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Package Display Panel-15 mg 30 count Bottle</span></p>
<p>NDC 64764-570-30<br>30 Tablets<br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Brintellix</span><br>vortioxetine<br>tablets<br>15 mg*</p>
<p><span class="Bold">Attention: Dispense with the<br>accompanying Medication Guide.</span></p>
<p><span class="Italics">Takeda logo</span><br><span class="Italics">Lundbeck logo</span></p>
<p>Lot</p>
<p>Exp.</p>
<p>Product of</p>
<p>L252-02</p>
<p>*Each orange tablet contains: 19.065 mg vortioxetine hydrobromide (equivalent<br>to 15 mg vortioxetine).<br>Dist. and Mktd. by: <span class="Bold">Takeda Pharmaceuticals America, Inc.,</span> Deerfield, IL 60015<br>Mktd. by: <span class="Bold">Lundbeck,</span> Deerfield, IL 60015<br>BRINTELLIX is a trademark of H. Lundbeck A/S registered with the U.S Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>Tamper-evident: Do not accept if seal over bottle opening is broken or missing.<br>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP<br>Controlled Room Temperature].<br><span class="Bold">Usual Dosage:</span> See package insert.</p>
<p><span class="Italics">barcode</span></p>
<div class="Figure">
<a name="id20795126"></a><img alt="15mg-30ct.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f342de2c-e54a-4073-8baf-db7b10bcfee8"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">Package Display Panel-20 mg 30 count Bottle</span></p>
<p>NDC 64764-580-30<br>30 Tablets<br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Brintellix</span><br>vortioxetine<br>tablets<br>20 mg*</p>
<p><span class="Bold">Attention: Dispense with the<br>accompanying Medication Guide.</span></p>
<p><span class="Italics">Takeda logo</span><br><span class="Italics">Lundbeck logo</span></p>
<p>Lot</p>
<p>Exp.</p>
<p>Product of</p>
<p>L256-02</p>
<p>*Each red tablet contains: 25.42 mg vortioxetine hydrobromide (equivalent<br>to 20 mg vortioxetine).<br>Dist. And Mktd. By: <span class="Bold">Takeda Pharmaceuticals America, Inc.,</span> Deerfield, IL 60015<br>Mktd. By: <span class="Bold">Lundbeck,</span> Deerfield, IL 60015<br>BRINTELLIX is a trademark of H. Lundbeck A/S registered with the U.S Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>Tamper-evident: Do not accept if seal over bottle opening is broken or missing.<br>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP<br>Controlled Room Temperature].<br><span class="Bold">Usual Dosage:</span> See package insert.</p>
<p><span class="Italics">barcode</span></p>
<div class="Figure">
<a name="id20795131"></a><img alt="20mg-30ct.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3&amp;name=image-11.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BRINTELLIXÂ 		
					</strong><br><span class="contentTableReg">vortioxetine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-550</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VORTIOXETINE HYDROBROMIDE</strong> (VORTIOXETINE) </td>
<td class="formItem">VORTIOXETINE</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (almond shaped biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5;TL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-550-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-550-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-550-77</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-550-09</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:64764-550-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204447</td>
<td class="formItem">10/02/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BRINTELLIXÂ 		
					</strong><br><span class="contentTableReg">vortioxetine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-560</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VORTIOXETINE HYDROBROMIDE</strong> (VORTIOXETINE) </td>
<td class="formItem">VORTIOXETINE</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (almond shaped biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10;TL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-560-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-560-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-560-77</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-560-09</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:64764-560-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204447</td>
<td class="formItem">10/02/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BRINTELLIXÂ 		
					</strong><br><span class="contentTableReg">vortioxetine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-570</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VORTIOXETINE HYDROBROMIDE</strong> (VORTIOXETINE) </td>
<td class="formItem">VORTIOXETINE</td>
<td class="formItem">15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (almond shaped biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">15;TL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-570-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-570-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-570-77</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-570-09</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:64764-570-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204447</td>
<td class="formItem">10/02/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BRINTELLIXÂ 		
					</strong><br><span class="contentTableReg">vortioxetine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-580</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VORTIOXETINE HYDROBROMIDE</strong> (VORTIOXETINE) </td>
<td class="formItem">VORTIOXETINE</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (almond shaped biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">20;TL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-580-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-580-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-580-77</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-580-09</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:64764-580-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204447</td>
<td class="formItem">10/02/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Takeda Pharmaceuticals America, Inc.
							(830134016)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cc70d6dd-e54b-483d-83f5-762a6cce455a</div>
<div>Set id: 4b0700c9-b417-4c3a-b36f-de461e125bd3</div>
<div>Version: 5</div>
<div>Effective Time: 20140728</div>
</div>
</div>Â <div class="DistributorName">Takeda Pharmaceuticals America, Inc.</div></p>
</body></html>
